Adakveo, 1st Sickle Cell Treatment for Pain Crises in Teens and Adults, Approved by FDA
Adakveo (crizanlizumab), which works to lower the frequency of painful vaso-occlusive crises (VOCs) common in sickle cell disease, has been approved by the FDA. Read the full story here.
What do you think of this news?
Sorry, there were no replies found.
Log in to reply.